CD8A and neoplasm: Several research reports have illustrated that in a subgroup of patients with NSCLC having an extensive percentage of CD8+ T cells, only the ones having a high density and tumor-infiltrating lymphocyte- (TIL-) associated dendritic cells (DCs) have substantial clinical advantages as opposed to patients having a lower DC density [17].